A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis

NCT06815380 · clinicaltrials.gov ↗
RECRUITING
Status
1000
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Almirall, S.A.